首页> 美国卫生研究院文献>Case Reports in Gastroenterology >Is Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites?
【2h】

Is Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites?

机译:姑息性腹腔镜高温腹腔化疗对恶性出血性腹水有效吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant hemorrhagic ascites may complicate the terminal evolution of digestive cancers with peritoneal carcinomatosis. It has a bad influence on prognosis and may severely impair patients’ quality of life. Palliative laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed to treat debilitating malignant ascites. Two cases of peritoneal carcinomatosis causing hemorrhagic ascites and severe anemia that needed iterative blood transfusions are reported. These patients were treated by laparoscopic HIPEC (mitomycin C and cisplatin with an inflow temperature of 43°C), resulting in cessation of peritoneal bleeding. No postoperative complication or relapse of ascites occurred during the following months. No more blood transfusion was needed. Laparoscopic HIPEC might be an effective and safe therapeutic option to consider in patients with malignant hemorrhagic ascites.
机译:恶性出血性腹水可能使具有腹膜癌变的消化道癌症的晚期进化复杂化。它对预后有不良影响,并可能严重损害患者的生活质量。已提出姑息性腹腔镜热腹膜内化疗(HIPEC)来治疗使人衰弱的恶性腹水。据报道有两例腹膜癌病,引起腹水和严重贫血,需要反复输血。这些患者接受了腹腔镜HIPEC(丝裂霉素C和顺铂,流入温度为43°C)治疗,从而停止了腹膜出血。在接下来的几个月中,没有发生术后并发症或腹水复发。不再需要输血。腹腔镜HIPEC可能是恶性出血性腹水患者考虑的一种安全有效的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号